Top Buy Now Summary References
Home
>
Section
>
Chapter

Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database

Falcone, F.; Breda, E.; Ferrandina, G.; Malzoni, M.; Perrone, A.M.; Cormio, G.; Di Donato, V.; Frigerio, L.; Mangili, G.; Raspagliesi, F.; Festi, A.; Scibilia, G.; Biglia, N.; Sorio, R.; Vizza, E.; Losito, N.S.; Greggi, S.

Gynecologic Oncology 161(3): 825-831

2021

ISSN/ISBN: 1095-6859
PMID: 33781554
DOI: 10.1016/j.ygyno.2021.03.023
Accession: 079147402

Full-Text Article emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II-III serous borderline ovarian tumors (BOTs). A multi-institutional retrospective study was conducted within the MITO Group. A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91-179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5-57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6-167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT. Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.

References

Falcone, F.; Malzoni, M.; Carnelli, M.; Cormio, G.; De Iaco, P.; Di Donato, V.; Ferrandina, G.; Raspagliesi, F.; Sorio, R.; Losito, N.S.; Greggi, S. 2022: Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database Gynecologic Oncology 165(2): 302-308
Lu, Z.; Li, B.; Gu, C. 2019: Outcomes of fertility-sparing surgery for stage Ii and IIi serous borderline ovarian tumors Journal of International Medical Research 47(10): 4895-4903
Uzan, C.; Muller, E.; Kane, A.; Gouy, S.; Bendifallah, S.; Fauvet, R.; Darai, E.; Morice, P. 2013: Fertility sparing treatment of recurrent stage i serous borderline ovarian tumours Human Reproduction 28(12): 3222-3226
Huang, Y.; Zhang, W.; Wang, Y. 2016: The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: a meta-analysis Taiwanese Journal of Obstetrics and Gynecology 55(3): 319-325
Jia, S-Zheng.; Xiang, Y.; Yang, J-Jun.; Shi, J-Hua.; Jia, C-Wei.; Leng, J-Hua. 2020: Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study Human Reproduction 35(2): 328-339
Ko, M.-E.; Lin, Y.-H.; Huang, K.-J.; Chang, W.-C.; Sheu, B.-C. 2023: Fertility and Pregnancy Outcomes after Fertility-Sparing Surgery for Early-Stage Borderline Ovarian Tumors and Epithelial Ovarian Cancer: a Single-Center Study Cancers 15(22)
Yu, X.-P.; Liu, Y.; Jiao, J.-W.; Yang, H.-J.; Wang, R.-J.; Zhang, S. 2020: Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage i Serous Borderline Tumors and Stage i Serous Malignant Tumors Presenting as Solid-Cystic Mass Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 26: E924497
Gershenson, D.M.; Deavers, M.; Diaz, S.; Tortolero-Luna, G.; Miller, B.E.; Bast, R.C.; Mills, G.B.; Silva, E.G. 1999: Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 5(12): 4053-4058
Liu, F.; Hu, D.H.; Zhang, Y.F.; Wang, B.; Huang, K.; Wang, C.Y.; Xia, X.Y. 2017: A retrospective study of tumor and fertility outcomes after fertility-sparing surgical treatment of patients with borderline ovarian tumors Zhonghua Yi Xue Za Zhi 97(47): 3699-3703
Kane, A.; Uzan, C.; Gouy, S.; Pautier, P.; Duvillard, P.; Morice, P. 2010: Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary Fertility and Sterility 94(7): 2891-2894
Vandenput, I.; Amant, F.; Vergote, I. 2005: Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy Gynecologic Oncology 98(3): 523; Author Reply 524-5
Bendifallah, S.; Ballester, M.; Uzan, C.; Fauvet, R.; Morice, P.; Darai, E. 2014: Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors American Journal of Obstetrics and Gynecology 211(6): 637.E1
Halperin, R.; Zehavi, S.; Dar, P.; Habler, L.; Hadas, E.; Bukovsky, I.; Schneider, D. 2001: Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas European Journal of Gynaecological Oncology 22(4): 292-296
Seidman, J.D.; Kurman, R.J. 1996: Subclassification of ovarian serous borderline tumors into benign and malignant types A clinicopathologic study of 65 advanced stage cases Modern Pathology 9(1): 97A
Camatte, S.; Morice, P.; Pautier, P.; Atallah, D.; Duvillard, P.; Castaigne, D. 2002: Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary Bjog: An International Journal of Obstetrics and Gynaecology 109(4): 376-380
Nakai, G.; Yamada, T.; Yamamoto, K.; Hirose, Y.; Ohmichi, M.; Narumi, Y. 2018: MRi appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation Journal of Ovarian Research 11(1): 7
Prat, J. 2014: The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(7): 1255-1258
Prat, J. 2014: The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(7): 1255-1258
Uzan, C.; Kane, A.; Rey, A.; Gouy, S.; Duvillard, P.; Morice, P. 2010: Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary Annals of Oncology: Official Journal of the European Society for Medical Oncology 21(1): 55-60